Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC (TRIBE2)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02339116 |
Recruitment Status : Unknown
Verified February 2020 by Gruppo Oncologico del Nord-Ovest.
Recruitment status was: Active, not recruiting
First Posted : January 15, 2015
Last Update Posted : February 5, 2020
|
Sponsor:
Gruppo Oncologico del Nord-Ovest
Information provided by (Responsible Party):
Gruppo Oncologico del Nord-Ovest
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet
publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending
Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during
QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review
assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific
validity or relevance of the submitted information.
Recruitment Status : | Unknown |
---|---|
Actual Primary Completion Date : | May 15, 2017 |
Estimated Study Completion Date : | February 2021 |
Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
---|---|---|
1 |
January 28, 2021 | February 18, 2021 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):